Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
10 October 2013Website:
http://www.macrogenics.comNext earnings report:
06 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 27 Sep 2024 22:24:31 GMTDividend
Analysts recommendations
Institutional Ownership
MGNX Latest News
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104928&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104874&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104815&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104807&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104738&wire=1 or contact Joseph E. Levi, Esq.
SAN FRANCISCO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now.
NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of a class action securities lawsuit.
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX).
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104700&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the “Class Period”), of the important September 24, 2024 lead plaintiff deadline.
What type of business is MacroGenics?
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
What sector is MacroGenics in?
MacroGenics is in the Healthcare sector
What industry is MacroGenics in?
MacroGenics is in the Biotechnology industry
What country is MacroGenics from?
MacroGenics is headquartered in United States
When did MacroGenics go public?
MacroGenics initial public offering (IPO) was on 10 October 2013
What is MacroGenics website?
https://www.macrogenics.com
Is MacroGenics in the S&P 500?
No, MacroGenics is not included in the S&P 500 index
Is MacroGenics in the NASDAQ 100?
No, MacroGenics is not included in the NASDAQ 100 index
Is MacroGenics in the Dow Jones?
No, MacroGenics is not included in the Dow Jones index
When was MacroGenics the previous earnings report?
No data
When does MacroGenics earnings report?
The next expected earnings date for MacroGenics is 06 November 2024